A Meaningful Shift In FDA's Biosimilarity Analysis
By Theodore Thompson · January 5, 2026, 4:22 PM EST
The U.S. Food and Drug Administration's October draft guidance on biosimilar biologic license applications signals a meaningful shift in how the agency will analyze biosimilarity and interchangeability.[1]...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login